venture fund, Lilly and Andreessen Horowitz

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...
Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...
Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with ...
Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Though we’re well into the winter season, Lilly Pulitzer always finds a way to get us excited for spring and summer. The ...
Forty submissions, weeks of polls and several thousand votes from Herald-Leader subscribers have finally brought us to this ...
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...